NCT06144567View on ClinicalTrials.gov

Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis

Not yet recruitingOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Psoriatic Arthritis
Interventions
DRUG

Upadacitinib

As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.

Trial Locations (1)

28040

Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid

All Listed Sponsors
collaborator

Hospital Universitario de Móstoles

OTHER

lead

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

NCT06144567 - Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis | Biotech Hunter | Biotech Hunter